Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Monday.

Several other research firms have also weighed in on BLCM. Wells Fargo & Company reiterated an “outperform” rating and issued a $31.00 target price on shares of Bellicum Pharmaceuticals in a report on Tuesday, June 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $35.00 target price on shares of Bellicum Pharmaceuticals in a report on Monday, June 26th. Ladenburg Thalmann Financial Services set a $31.00 target price on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, June 24th. Raymond James Financial, Inc. reiterated a “buy” rating on shares of Bellicum Pharmaceuticals in a report on Tuesday, June 27th. Finally, BidaskClub lowered shares of Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, July 6th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Bellicum Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $26.20.

Shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) opened at 12.69 on Monday. The company has a 50-day moving average of $9.61 and a 200-day moving average of $11.71. The stock’s market capitalization is $421.64 million. Bellicum Pharmaceuticals has a 52-week low of $7.41 and a 52-week high of $23.11.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same quarter last year, the business earned ($0.61) earnings per share. Equities research analysts anticipate that Bellicum Pharmaceuticals will post ($3.02) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/valuengine-upgrades-bellicum-pharmaceuticals-inc-blcm-to-sell/1574674.html.

In other news, VP Ken Moseley sold 13,823 shares of the business’s stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $12.26, for a total value of $169,469.98. Following the sale, the vice president now directly owns 14,314 shares of the company’s stock, valued at approximately $175,489.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David M. Spencer sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 10th. The shares were sold at an average price of $11.54, for a total transaction of $115,400.00. The disclosure for this sale can be found here. Insiders sold a total of 24,260 shares of company stock worth $290,048 over the last three months. Insiders own 23.30% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Ronald Blue & Co. LLC purchased a new stake in shares of Bellicum Pharmaceuticals in the 2nd quarter valued at approximately $117,000. Clear Harbor Asset Management LLC purchased a new stake in shares of Bellicum Pharmaceuticals in the 2nd quarter valued at approximately $118,000. Knott David M purchased a new stake in shares of Bellicum Pharmaceuticals in the 1st quarter valued at approximately $131,000. Voya Investment Management LLC purchased a new stake in shares of Bellicum Pharmaceuticals in the 2nd quarter valued at approximately $132,000. Finally, American International Group Inc. raised its stake in shares of Bellicum Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 852 shares during the period. 55.73% of the stock is currently owned by institutional investors and hedge funds.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.